GlaxoSmithKline to fight US drug patent ruling
GlaxoSmithKline is to fight a US court ruling which invalidates patents for its Augmentin antibiotic drug.
Teva Pharmaceuticals Industries, Geneva Pharmaceuticals and Ranbaxy Laboratories sued to invalidate three patents that protected Augmentin from generic competition until the end of this year.